검색
Alnylam Pharmaceuticals Inc
ALNY관심 목록에 추가
293.626USD
+1.596+0.55%
시장 운영 시간 （ET）시세는 15분 지연됩니다
39.18B시가총액
71.87P/E TTM
자세한 내용은 Alnylam Pharmaceuticals Inc 회사
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc 정보
종목 코드 ALNY
회사 이름Alnylam Pharmaceuticals Inc
상장일May 28, 2004
CEOGreenstreet (Yvonne L)
직원 수2230
유형Ordinary Share
회계 연도 종료May 28
주소675 W Kendall St
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02142-1168
전화16175518200
웹사이트https://www.alnylam.com/
종목 코드 ALNY
상장일May 28, 2004
CEOGreenstreet (Yvonne L)
Alnylam Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
-21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
-569.85%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Dr. Kevin Fitzgerald, Ph.D.
Dr. Kevin Fitzgerald, Ph.D.
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
3.64K
-21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
136.00
-569.85%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Mon, Apr 6
통화: USD마지막 업데이트: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
사업별USD
이름
수익
비율
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
기타
286.75M
7.72%
지역별USD
이름
수익
비율
United States
2.07B
55.67%
Europe
651.09M
17.53%
Net revenues from collaborations
553.37M
14.90%
Rest of World
267.93M
7.21%
Royalty revenue
174.02M
4.69%
사업별
지역별
사업별USD
이름
수익
비율
AMVUTTRA
2.31B
62.30%
Roche
394.88M
10.63%
GIVLAARI
308.49M
8.31%
Other
218.55M
5.88%
OXLUMO
191.44M
5.15%
기타
286.75M
7.72%
주식 보유 통계
마지막 업데이트: Sun, May 10
마지막 업데이트: Sun, May 10
주주
주주 유형
주주
주주
비율
Capital World Investors
12.21%
Fidelity Management & Research Company LLC
11.30%
BlackRock Institutional Trust Company, N.A.
5.27%
Capital Research Global Investors
5.08%
Vanguard Portfolio Management, LLC
4.86%
기타
61.28%
주주
주주
비율
Capital World Investors
12.21%
Fidelity Management & Research Company LLC
11.30%
BlackRock Institutional Trust Company, N.A.
5.27%
Capital Research Global Investors
5.08%
Vanguard Portfolio Management, LLC
4.86%
기타
61.28%
주주 유형
주주
비율
Investment Advisor
66.80%
Investment Advisor/Hedge Fund
22.94%
Hedge Fund
3.64%
Sovereign Wealth Fund
1.83%
Research Firm
1.79%
Pension Fund
1.47%
Bank and Trust
1.46%
Private Equity
0.22%
Individual Investor
0.17%
기관 주식 보유
마지막 업데이트: Sun, Apr 5
마지막 업데이트: Sun, Apr 5
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
1634
133.66M
100.11%
-6.05M
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital World Investors
16.30M
12.29%
-132.48K
-0.81%
Dec 31, 2025
Fidelity Management & Research Company LLC
15.08M
11.37%
-821.92K
-5.17%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
7.04M
5.31%
+453.92K
+6.89%
Dec 31, 2025
Capital Research Global Investors
6.78M
5.11%
-443.13K
-6.14%
Dec 31, 2025
JP Morgan Asset Management
4.00M
3.01%
+130.78K
+3.38%
Dec 31, 2025
State Street Investment Management (US)
3.23M
2.43%
+147.48K
+4.79%
Dec 31, 2025
Invesco Capital Management (QQQ Trust)
2.81M
2.12%
-68.68K
-2.39%
Feb 28, 2026
Geode Capital Management, L.L.C.
2.65M
2%
+151.48K
+6.06%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
더 보기
Global X Genomics & Biotechnology ETF
비율6.48%
ProShares Ultra Nasdaq Biotechnology
비율5.81%
Invesco Nasdaq Biotechnology ETF
비율5.77%
Franklin Genomic Advancements ETF
비율5.35%
iShares Biotechnology ETF
비율5.07%
VanEck Biotech ETF
비율4.56%
American Century Focused Dynamic Growth ETF
비율3.76%
Goldman Sachs Future Health Care Equity ETF
비율3.42%
First Trust NYSE Arca Biotechnology Index Fund
비율3.33%
Invesco NASDAQ Next Gen 100 ETF
비율3.28%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
